Read More

Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study

Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the company has decided not to 

KRON

Read More

FY24 Election Is A Major Game Changer For US Renewable Sector: Piper Analyst

Piper Sandler analyst Kashy Harrison revised the rating on several Renewables & Alternative Energy companies. The analyst sees benefits accruing to the installers initially (FY24) and inverters eventually (FY25), with the rest of the stock in the coverage benefiting in the long term.

ARRY

Read More

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.

AFRM